Table 1 Characteristics of study population according to the presence of lymphopaenia on admission
All (n = 377) | Lymphopaenia (n = 151) | No lymphopaenia (n = 226) | p value | |
|---|---|---|---|---|
Age (years) | 62 [52–75] | 69 [54–78] | 59 [51–71] | <0.001 |
Weight (kg) | 76 [67–85] | 75 [67–82] | 77 [67–88] | 0.22 |
Male, n (%) | 263 (70) | 105 (70) | 158 (70) | 0.51 |
Witnessed CA, n (%) | 318 (84) | 132 (87) | 186 (82) | 0.12 |
Bystander CPR, n (%) | 249 (66) | 110 (73) | 139 (62) | 0.02 |
Time to ROSC (min) | 15 [8–25] | 10 [5–21] | 18 [10–27] | <0.001 |
Adrenaline (mg) | 3 [2–6] | 3 [1–5] | 4 [2–7] | <0.001 |
Out-of-hospital CA, n (%) | 211 (56) | 60 (40) | 151 (67) | <0.001 |
Cardiac origin of arrest, n (%) | 227 (60) | 80 (53) | 147 (65) | 0.01 |
Shockable rhythm, n (%) | 145 (38) | 41 (27) | 104 (46) | <0.001 |
Comorbidities | ||||
Chronic heart failure, n (%) | 81 (21) | 37 (25) | 44 (19) | 0.15 |
Hypertension, n (%) | 171 (45) | 78 (52) | 93 (41) | 0.03 |
Coronary artery disease, n (%) | 164 (44) | 62 (41) | 102 (45) | 0.25 |
Diabetes, n (%) | 92 (24) | 48 (32) | 44 (19) | 0.01 |
COPD/asthma, n (%) | 66 (18) | 31 (21) | 35 (15) | 0.13 |
Neurological disease, n (%) | 64 (17) | 31 (21) | 32 (14) | 0.05 |
Chronic renal disease, n (%) | 67 (18) | 36 (24) | 31 (14) | 0.008 |
Liver cirrhosis, n (%) | 22 (6) | 14 (9) | 8 (4) | 0.02 |
HIV, n (%) | 1 (0) | 1 (1) | 0 | 0.40 |
Corticosteroid therapy, n (%) | 73 (19) | 41 (27) | 32 (14) | 0.001 |
Other immunosuppressive agents, n (%) | 15 (4) | 11 (7) | 4 (2) | 0.008 |
Initial blood analysis | ||||
White blood cells count (/mm3) | 12,200 [9000–16,700] | 10,700 [7700–14,500] | 13,100 [9925–17,475] | 0.06 |
Neutrophils (/mm3) | 9400 [6300–13,500] | 9100 [6500–13,200] | 9915 [5947–13,700] | <0.001 |
Haemoglobin (g/dL) | 12.0 [9.9–13.7] | 10.6 [8.9–12.9] | 12.8 [10.8–14.1] | 0.04 |
Platelets (*103/mm3) | 193 [127–264] | 158 [100–230] | 210 [147–285] | <0.001 |
C-reactive protein (mg/dL) | 9 [2–52] | 29 [4–93] | 5 [2–22] | <0.001 |
Lactate (mEq/L) | 4.3 [2.8–7.9] | 4.1 [2.6–7.8] | 4.5 [2.9–7.9] | 0.20 |
During ICU stay | ||||
Infection, n (%) | 215 (57) | 100 (66) | 115 (51) | 0.002 |
IABP, n (%) | 27 (7) | 6 (4) | 21 (9) | 0.04 |
ECMO, n (%) | 51 (14) | 23 (15) | 28 (12) | 0.26 |
Shock, n (%) | 205 (54) | 90 (60) | 115 (51) | 0.06 |
Acute kidney injury, n (%) | 228 (60) | 100 (66) | 128 (57) | 0.04 |
CRRT, n (%) | 57 (15) | 30 (20) | 27 (12) | 0.03 |
Vasopressor therapy, n (%) | 274 (73) | 120 (79) | 154 (68) | 0.01 |
Dobutamine therapy, n (%) | 200 (53) | 85 (56) | 115 (51) | 0.18 |
Outcomes | ||||
Total ICU stay (days) | 4 [2–8] | 4 [2–8] | 4 [2–8] | 0.93 |
ICU mortality, n (%) | 217 (58) | 95 (63) | 122 (54) | 0.05 |
Hospital mortality, n (%) | 235 (62) | 103 (68) | 132 (58) | 0.03 |
Favourable outcome at 3 months, n (%) | 131 (35) | 43 (28) | 88 (39) | 0.02 |